Compare SNOA & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNOA | BIAF |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | N/A | 57 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 5.3M |
| IPO Year | 2006 | N/A |
| Metric | SNOA | BIAF |
|---|---|---|
| Price | $2.86 | $1.02 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.9K | ★ 277.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,288,000.00 | N/A |
| Revenue This Year | $23.00 | N/A |
| Revenue Next Year | $24.59 | $20.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.19 | N/A |
| 52 Week Low | $1.77 | $0.16 |
| 52 Week High | $6.92 | $13.50 |
| Indicator | SNOA | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 39.30 | 47.93 |
| Support Level | $2.80 | $0.90 |
| Resistance Level | $3.85 | $1.45 |
| Average True Range (ATR) | 0.13 | 0.14 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 40.48 | 35.77 |
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.